Breaking News
Home / Medical News (page 4)

Medical News

Specialty Therapies Drive Significant Increase in US Drug Spending in 2014

Spending on specialty drugs took a record rise in the US in 2014, largely due to new expensive, yet effective, hepatitis C drugs, according to new data released today in the 2014 Express Scripts Drug Trend Report. According to the pharmacy benefit manager’s (PBM) report, new hepatitis C drugs’ high …

Read More »

Quest Diagnostics Announces Availability of Exclusive Whole Exome Sequencing Service for Diagnosis of Pediatric Neurological Disorders

Quest Diagnostics announced that it is now offering a whole exome sequencing service aimed to enhance the diagnosis of rare neurological disorders in pediatric population. The leading provider of diagnostic information services today announced the availability of Neurome, a whole exome sequencing service. Leading genomics-based diagnostic laboratory, Personalis, Inc. developed …

Read More »

CTI BioPharma and Baxter’s Myelofibrosis Drug Meets Primary Endpoint in Late-Stage Trial

Baxter International and CTI BioPharma Corp. announced that its experimental blood cancer drug met its primary endpoint in a late-stage study. The companies announced top-line results for the primary endpoint from PERSIST-1, a Phase III registration clinical trial evaluating pacritinib, an oral JAK2/FLT3 multikinase inhibitor, for the treatment of patients …

Read More »

Novogen’s Brain Cancer Drug Demonstrates Promising Results

Australian biotechnology company Novogen Limited’s lead candidate demonstrated promising results in patients with brain cancer. The company announced that one of its lead candidate products, TRXE-009, is showing the potential to become an important new therapy in the fight against adult and pediatric brain cancer. The pre-clinical study has found …

Read More »

Specialty Pharma Journal Launches its Rebranded Logo and Website

Specialty Pharma Journal (SPJ) today announced the launch of its new name, Specialty Precision & Technology Pharma Journal, along with a rebranding initiative which includes a new logo and website. The change reflects the publication’s focus on “precision medicine,” a new healthcare model that uses innovative technologies to tailor treatment …

Read More »

AbbVie Strengthens Cancer Portfolio with its $21 Billion Acquisition of Pharmacyclics

AbbVie Inc. announced late Wednesday that it will purchase cancer drugmaker Pharmacyclics for roughly $21 billion. AbbVie will pay $216.25 per share in cash and stock, a 13 percent premium to Pharmacyclics’ Wednesday close. In exchange AbbVie will gain one of the world’s top-selling cancer drugs Imbruvica. The acquisition strengthens …

Read More »

FDA Grants Early Approval to Bristol-Myers Squibb’s Opdivo for Lung Cancer

The US Food and Drug Administration (FDA) expanded approval of Bristol-Myers Squibb’s (BMS) Opdivo (nivolumab) to treat patients with advanced squamous non-small cell lung cancer (NSCLC). The approval comes just days after the agency accepted BMS’ application and granted the drug priority review. The FDA was scheduled to make a …

Read More »

Mayo and Gentag Partner to Develop Wearable Biosensors for Treating Diabetes

Mayo Clinic and Gentag, Inc. have teamed up to develop next-generation, wearable biosensors designed to fight diabetes and obesity. The companies have reached a joint intellectual property (IP) agreement to develop the first-of-its-kind, wearable patch sensors, which are wireless and the size of a small bandage. The sensors are designed …

Read More »

Gene Mutation May Predict Immunotherapy Outcome in Melanoma Patients

Melanoma patients whose tumors had a specific gene mutation demonstrated better response and treatment outcomes when treated with immunotherapies, according to a new study. Researchers found that among melanoma patients who were treated with immunotherapies, individuals whose tumors had mutations in the NRAS gene responded better to treatment compared to …

Read More »

Blueprint Medicines and Alexion Partner for Drugs Targeting a Rare Genetic Disease

Rare disease maker Alexion Pharmaceuticals has partnered with Blueprint Medicines to develop drugs for a rare genetic disease. Blueprint Medicines said that the companies have formed a strategic collaboration to discover, develop and commercialize novel drug candidates for an undisclosed activated kinase target, which causes a rare genetic disease. Blueprint …

Read More »